Last $3.59 USD
Change Today 0.00 / 0.00%
Volume 0.0
NBS On Other Exchanges
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/14 - $7.98
52 Week Low
12/12/14 - $3.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $945.0K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Vice President of Strategic Transactions
Total Annual Compensation: $319.6K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Appoints Peter G. Traber as Director

Neostem, Inc. announced the addition of Peter G. Traber to its Board of Directors. Dr. Traber has experience in medicine, science and the pharmaceutical industry. He is currently President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics. Notably, he is president emeritus of Baylor College of Medicine, where he was Chief Executive Officer from 2003 to 2008. Dr. Traber also has extensive big pharma leadership experience serving from 2000 to 2003 as Senior Vice President of clinical development and medical affairs and Chief Medical Officer of GlaxoSmithKline. He has also served as CEO of the University of Pennsylvania Health System, Chair of the Department of Internal Medicine, and Chief of Gastroenterology for the University of Pennsylvania School of Medicine.

NeoStem, Inc. Receives Drug Manufacture License for Irvine Facility

NeoStem, Inc. announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T (also known as NBS20) and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the Company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma. Eltrapuldencel-T is an autologous immunotherapy intended to eliminate cancer-initiating (stem) cells capable of causing disease recurrence and progression. Creation of the therapy begins with cancer-initiating (stem) cells that have been isolated from the patient's resected tumor sample, enriched and inactivated. These newly created cancer-initiating (stem) cells are then combined with dendritic cells (antigen-presenting immune cells) derived from the patient's own blood, and granulocyte-macrophage colony stimulating factor (GM-CSF), a natural growth factor that stimulates white blood cells in the body. The product is then introduced back into the patient via a series of subcutaneous injections. The Intus Study is a multi-national, randomized, double-blind Phase 3 clinical trial in which patients will be randomized in a 2:1 ratio to receive either eltrapuldencel-T or a control treatment (autologous mononuclear cells in GM-CSF). An expected 250 enrolled patients throughout the U.S., Canada, Australia and New Zealand will receive weekly injections for three consecutive weeks, and then once monthly for five months. This investigational treatment, planned to be evaluated in the company's Phase 3 Intus study, has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration and will be conducted under a protocol that has been granted Special Protocol Assessment.

Neostem, Inc. and Invetech Pty. Ltd. Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing

NeoStem, Inc. and Invetech Pty Ltd. announced an agreement for the development of a new closed processing system (the ‘System’) for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market. The System will be applicable to a range of cell therapy processes in development and commercialization stages, and will consist of an instrumentation platform, disposable flow path, and operating and application software for automated execution of user-selected protocols. The System will provide a flexible small scale process suitable for GMP manufacturing of autologous and other patient-specific products where small scale is full scale, while also supporting efficient development of processes at lower cost prior to transitioning to scaled volumes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $3.59 USD 0.00

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.19 USD 0.00
Cesca Therapeutics Inc $1.01 USD 0.00
Cytori Therapeutics Inc $0.50 USD 0.00
Nuo Therapeutics Inc $0.32 USD 0.00
Vericel Corp $3.20 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at